Other formats:
BibTeX
LaTeX
RIS
@article{2306558,
author = {Kubeš, Václav and Křen, Leoš and Sokol, Filip and Michalka, Jozef and Mužík, Jan and Arpáš, Tomáš and Křenová, Zdenka and Král, Zdeněk},
article_location = {ATHENS},
article_number = {4},
doi = {http://dx.doi.org/10.21873/invivo.13261},
keywords = {Classic Hodgkin lymphoma; PD-L1 expression; treatment; overall survival; relapse},
language = {eng},
issn = {0258-851X},
journal = {In vivo},
title = {Prognostic Significance of Immune-checkpoint Molecule PD-L1 in Classical Hodgkin Lymphoma: A Clinicopathologic Study of 120 Cases},
url = {https://iv.iiarjournals.org/content/37/4/1735},
volume = {37},
year = {2023}
}
TY - JOUR
ID - 2306558
AU - Kubeš, Václav - Křen, Leoš - Sokol, Filip - Michalka, Jozef - Mužík, Jan - Arpáš, Tomáš - Křenová, Zdenka - Král, Zdeněk
PY - 2023
TI - Prognostic Significance of Immune-checkpoint Molecule PD-L1 in Classical Hodgkin Lymphoma: A Clinicopathologic Study of 120 Cases
JF - In vivo
VL - 37
IS - 4
SP - 1735-1742
EP - 1735-1742
PB - Greece : International Institute of Anticancer Research
SN - 0258851X
KW - Classic Hodgkin lymphoma
KW - PD-L1 expression
KW - treatment
KW - overall survival
KW - relapse
UR - https://iv.iiarjournals.org/content/37/4/1735
N2 - Background/Aim: Classic Hodgkin lymphoma (cHL) is a common B-cell malignancy. Despite the good prognosis, in some patients the standard chemotherapy and radiotherapy-based approach does not lead to long-term remission, and these patients eventually relapse. Moreover, the primary refractory disease is of major concern regarding prognosis. Patients and Methods: We performed a retrospective analysis to evaluate PD-L1 expression in 120 patients with classic Hodgkin lymphoma (cHL). Results: The median follow-up of the entire group of patients was 90 months. After initial therapy, complete remission was achieved in 113 (94.2%) patients. During the follow-up, cHL relapse/refractory disease was reported in 23 (19.2%) cases. A total of five patients died during the follow-up period, all from cHL progression. When determining PD-L1 expression on Hodgkin-Reed-Sternberg (HRS) cells, 37 cases (30.8%) were evaluated as negative, and 83 cases (69.2%) as positive. In the negative PD-L1 group of patients, no cHL relapse/refractory disease was observed during the follow -up period. However, out of 83 patients with positive PD-L1 expression on HRS cells, 23 (28%) showed relapse/refractory cHL. Conclusion: A significantly higher relapse rate was observed in PD-L1-positive patients diagnosed with cHL.
ER -
KUBEŠ, Václav, Leoš KŘEN, Filip SOKOL, Jozef MICHALKA, Jan MUŽÍK, Tomáš ARPÁŠ, Zdenka KŘENOVÁ and Zdeněk KRÁL. Prognostic Significance of Immune-checkpoint Molecule PD-L1 in Classical Hodgkin Lymphoma: A Clinicopathologic Study of 120 Cases. \textit{In vivo}. ATHENS: Greece : International Institute of Anticancer Research, 2023, vol.~37, No~4, p.~1735-1742. ISSN~0258-851X. Available from: https://dx.doi.org/10.21873/invivo.13261.
|
